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Purpose. We investigated stroke recurrence in patients with acute ischemic stroke of undetermined aetiology, with or without
a patent foramen ovale (PFO). Methods. Consecutive stroke patients underwent to Transcranial Doppler and Transesophageal
Echocardiography for PFO detection. Secondary stroke prevention was based on current guidelines. Results.P F Ow a sd e t e c t e di n
57/129 (44%) patients. The rate of recurrent stroke did not signiﬁcantly diﬀer between patients with and without a PFO: 0.0%
versus 1.4% (1 week), 1.7% versus 2.7% (1 month), and 3.5% versus 4.2% (3 months), respectively. The 2-year rates were 10.4%
(5/48) in medically treated PFO and 8.3% (6/72) in PFO-negative patients (P = 0.65), with a relative risk of 1.25. No recurrent
events occurred in 9 patients treated with percutaneous closure of PFO. Conclusion. PFO was not associated with increased rate
of recurrent stroke. Age-related factors associated with stroke recurrence in cryptogenic stroke should be taken into account when
patients older than 55 years are included in PFO studies.
1.Introduction
Controversy exists around the topic of PFO detection, its
associationwithcerebralischemia,andsecondaryprevention
strategies [1]. Treatment options in patients with PFO in-
clude antiplatelet agents, anticoagulants, surgical closure, or
percutaneous closure devices. A meta-analysis of the French
PFO/atrial septal aneurysm (ASA) and PICCS (Patent Fora-
men Ovale in Cryptogenic Stroke Study) indicates that the
risk of recurrent stroke or death after a cryptogenic stroke is
not diﬀerent for patients with a PFO compared to patients
without a PFO when treated with either aspirin or warfarin,
although aspirin is preferable (Class IIa, Level of Evidence B)
[2, 3]. Warfarin is reasonable for high-risk patients who have
other indications for oral anticoagulation such as those with
an underlying hypercoagulable state or evidence of lower
extremities/pelvic deep venous thrombosis (Class IIa, Level
of Evidence C) [4]. Similarly, a clear reduction in the event
rate by surgical or percutaneous closure of PFO as compared
to medical treatment has not been fully demonstrated [5, 6].
Insuﬃcientdata exist tomake arecommendation aboutPFO
closure following a ﬁrst ischemic stroke. PFO closure may be
considered for patients with recurrent cryptogenic stroke de-
spite optimal medical therapy (Class IIb, Level of Evidence
C).
However, pending the results of randomized controlled
trails [7, 8], patients with cryptogenic strokes and evidence
ofaPFOarevariablymanagedbasedontheexperienceofthe
single centre, the availability to perform timely and compre-
hensive ultrasound patient assessment, and the accessibility
of experienced interventional cardiologists. Discrepancies in
published data can be also explained by diﬀerent patient2 ISRN Neurology
selection criteria, accuracy in stroke diagnosis, inclusion of
patientsolderthan55years[9–12],andtimeelapsed between
the onset of stroke symptoms and PFO detection. To our
knowledge, there are few studies on PFO detection and treat-
ment in patients evaluated in the acute phase of an ischemic
stroke or shortly after a TIA, when the risk of stroke recur-
rence is high [13, 14].
Aims of this study were (i) to investigate clinical and out-
come measures in patients with and without a PFO among
patients with undetermined stroke etiology, (ii) to compare
the rate of recurrent cerebrovascular events in the short-
term (i.e., at 1 week, 1 month, and 3 months) and long-term
(i.e., at two years) period between medically treated PFO and
PFO-negativepatients,and(iii)toassesstherateofrecurrent
adverse events in a small subgroups of patients who were
treated with percutaneous PFO closure.
2.MaterialsandMethods
Patients were selected from consecutive patients admitted to
our stroke unit within 24 hours from symptom onset. Demo-
graphics and clinical data were collected. Stroke severity
was assessed by the NIH Stroke Scale (NIHSS) and the
modiﬁed Rankin Score (mRS). Routine diagnostic eval-
uation included telemetry, ultrasound echocolor Doppler
study of the intracranial and extracranial vessels, and two-
dimensional transthoracic echocardiography (TTE). Brain
MRI with diﬀusion-weighted (DW) and perfusion-weighted
(PW) images and MR angiogram (MRA) of the intracranial
vesselswereperformed,ifnotcontraindicated.Ancillarytests
as screening for prothrombotic abnormalities (protein C
deﬁciency, protein S deﬁciency, anti-thrombin III deﬁciency,
factor V Leiden, and prothrombin 20210GA mutation, anti-
cardiolipin IgM and IgG antibodies), autoimmunity, or
collagenopathy were performed if clinically indicated. Stroke
etiology was based on the Trial of Org 10172 in Acute
Stroke Treatment, or TOAST criteria [15] on completion of
diagnostic tests.
Eligible patients were those with no history of classic
vascular risk factors (“pure” cryptogenic) as well as patients
with the following MRI characteristics: (i) single subcortical
lesion (<15mm lesion) despite well-controlled vascular risk
factors for small vessel disease (hypertension, diabetes), (ii)
large (≥15mm lesion) or scattered ischemic lesions in 1
vascular territory, and (iii) multiple ischemic lesions in
multiple vascular territories [16, 17]. Patients in groups (ii)
and(iii)hadnoevidenceofartery-to-arteryembolism(high-
grade large artery stenosis, ulcerated or complicated plaque,
or arterial dissection) or cardioembolic sources (atrial ﬁbril-
lation, intracardiac thrombus, endocarditis, hypokinetic left
ventricle wall, or ejection fraction inferior to 30%) despite
coexisting classic vascular risk factors not explaining the
clinical syndrome.
The contrast-enhanced Transcranial Doppler ultrasound
(c-TCD) and contrast-enhanced Trans-Esophageal Ecocar-
diography (c-TEE) protocols we have adopted to detect
PFO have been previously described [18]. Brieﬂy, c-TCD
monitoring for embolic signals passing through the middle
cerebral artery (MCA) was performed using a Trans-Cranial
and Vascular DWL Doppler System (Compumedics Ger-
many GmbH). According to a standardized examination
procedure [19], c-TCD was performed at rest and after
Valsalva manoeuvre, using an 18-gauge needle inserted into
the cubital vein with the patient in the supine position.
The contrast agent was prepared using 9mL isotonic saline
solution, 1mL of air, and 1mL autologous blood agitated
by two syringes attached via a 3-way stopcock and injected
a sab o l u s .A l ls t u d i e sw e r ea n a l y z e db yt w oo b s e r v e r s( F S ,
SDL). Severity of the RLS was deﬁned based on the number
of passing microbubbles (MB) in four categories: (i) absent
(zeroMB), (ii) mild (1 to 10MB), (iii) moderate (>10MB
without curtain), and (iv) severe (“curtain” or “shower”).
All c-TEE studies were performed using a Philips Ultra-
sound System HD11 (Bothell, WA USA) by two cardiologists
(E. D. Marchis, M. Borzi) blinded to the results of the c-
TCD. During the exam the patients were alert or under mild
sedation (midazolam 0.1mg/kg). Local anaesthesia of the
pharynxwasobtainedinallpatientsbyxylocainespray0.1%.
An atrial septal aneurysm (ASA) was deﬁned as ≥11mm of
phasic septal excursion into either atrium [20, 21]. Severity
and direction of the interatrial shunts were deﬁned by color
Doppler at rest and after Valsalva manoeuvre, before and
after injection of agitated contrast saline solution (9mL of
isotonic saline, 1mL of air, and 1mL autologous blood)
rapidly injected into the antecubital vein by two syringes
attached via a 3-way stopcock. PFO was determined to be
present if on saline contrast injection there was appearance
ofatleast1microbubbleinleftatriumwithin3cardiaccycles
after opaciﬁcation of right atrium. The shunt was deﬁned
mild (<10 microbubbles), moderate (>10 microbubbles),
and severe (marked opaciﬁcation of the left atrium). PFOs
with either >2mm separation of septum secundum and
primum or >10 microbubbles appearing in the left atrium
were classiﬁed as large. All other PFOs were classiﬁed as
small. Patients who were not collaborating or had lack of
compliance to TEE underwent to contrast-enhanced Trans-
Thoracic Echocardiography (c-TTE) by Philips Ultrasound
System HD11 (Bothell, WA USA) from an experienced
cardiologist (E. D. Marchis) blinded to the results of the c-
TCD. Detection and grading of right-to-left shunt RLS was
based on the same criteria adopted for c-TEE.
2.1. Secondary Stroke Prevention and Clinical Follow-Up.
Treatment decision (medical therapy or percutaneous PFO
closure) was based on the current guidelines and patient
preference. Prescribed antiplatelets were daily acetylsalicylic
acid 100mg to 300mg or clopidogrel 75mg. Oral anti-
coagulants were prescribed to patients with recurrent strokes
despite antiplatelets, coexisting ASA, prothrombotic condi-
tions, or deep venous thrombosis (the target international
normalized ratio was between 2 and 3). Selected cases were
referred to experienced interventional cardiologists for per-
cutaneous closure of PFO. Follow-up clinical evaluations
were performed at 1, 3, 6, and 24 months after the index
event. At each time-point information on neurologicalISRN Neurology 3
Table 1: Diﬀerences in demographic, clinical, and vascular risk
factors between patients with a PFO conﬁrmed by combined
ultrasound approach and those with negative TCD study for RLS
(i.e., PFO-negative patients).
PFO (+)
patients
n = 57
PFO (−)
patients
n = 72
P value
Age, mean (±SD) y.o. 57 (±14) 60 (±14) 0.57
Age ≤ 55 y.o., n (%) 21 (37%) 26 (36%) 0.67
Female sex, n (%) 27 (48%) 25 (34%) 0.02
Vascular risk factors, n (%):
Hypertension∗ 28 (49%) 32 (50%) 0.59
Diabetes mellitus∗ 8 (14%) 12 (17%) 0.91
Hypercholesterolemia∗ 17 (30%) 12 (16%) 0.03
Smoking§ 21 (37%) 35 (48%) 0.12
On antiplatelets before stroke/TIA,
n (%) 14 (25%) 19 (26%) 0.86
Previous TIA or stroke, n (%) 11 (19%) 12 (17%) 0.52
On statins before stroke/TIA, n (%) 7 (12%) 5 (7%) 0.09
Previous ischemic lesions on MRI,
n (%) 39 (68%) 55 (76%) 0.25
∗Known before stroke or TIA.
§Current or past (less than 5 years) smoking.
and functional status, adverse events, compliance to the
prescribed medications, life-style changes (physical activity,
changes in diet and weight, and cigarette smoking cessation),
and information on vascular risk factor control were col-
lected. A recurrent ischemic stroke was considered in the
presence of acute onset of focal neurological signs of more
than 24 hours’ duration with evidence of a new ischemic
lesion on CT or MRI scan, or when new lesions were absent
butclinicalsyndromewasconsistentwithstroke.Arecurrent
TIA was considered in the presence of acute onset of focal
neurological signs of less than 24 hours’ duration with or
without evidence of a new ischemic lesion on DW-MRI scan.
For statistical analyses, we compared clinical, imaging,
and outcome measures between patients with and those
without a PFO using Student’s t-test (for quantitative vari-
ables), and contingency tables with Fisher’s test (for cate-
gorical variables). The rates of stroke recurrence or death in
the short period (i.e., at 1 week, 1 month, 3 months) and in
the long term (i.e., at two years) after the index event were
assessed. Factors independently associated with favourable
outcome (mRS ≤ 2) at 12 months were identiﬁed by logistic
regression analysis. ORs with 95% CIs were calculated. P<
0.05 was considered statistically signiﬁcant. The analysis was
performed by the Statistica 7 software.
3. Results
Over 18 months (January 2007 to June 2008) 674 patients
with a diagnosis of acute ischemic stroke or transient
ischemic attack (TIA) were admitted in our stroke unit.
There were 148/674 (22%) patients with uncertain stroke
etiology. Of them, 19/148 (13%) of patients were excluded
fromtheanalysisforcontraindicationstoMRIstudy(n = 10;
63%), lack of compliance to c-TEE or c-TTE (n = 5; 26%),
and dropout at follow-up evaluation (n = 4; 21%), leaving
129/148 (87%) eligible for the study. A PFO was detected in
57/129 (44%) patients. Compared to PFO-negative patients,
those with a PFO were more frequently females (48% versus
34%; P = 0.02), had similar vascular risk factors except
for higher occurrence of hypercholesterolemia (30% versus
16%; P = 0.03), and had lower NIHSS score at 24 hours (3
versus5;P = 0.04).Astatisticallynonsigniﬁcant tendencywas
observed for higher occurrence of stroke onset on awakening
in PFO patients (P = 0.09) (These results are shown in
Table 1). At logistic regression analysis (with age, sex, stroke
risk factors, presence of PFO, stroke severity, type, and
location of infarct as independent variables) NIHSS at onset
(OR 0.55; 95% CI, 0.31 to 0.80; P<0.001) and NIHSS at
24 hours (OR 0.70; 95% CI, 0.49 to 0.91; P<0.001) were
negativelyassociatedwithfavourableoutcomeaftertwoyears
(mRS ≤ 2).
Patients with a PFO were treated for secondary stroke
prevention based on the current guiding principle, also
taking into account the following aspects: patients’ age and
favourite therapeutic approach; previous history of TIA or
stroke and the presence of chronic ischemic lesions on MRI
scan, presence of vascular risk factors and if they were well
controlled before the index stroke or TIA, and degree of
the right-to-left shunt (RLS) on c-TCD and its correlation
with the morphological characteristics and amplitude of
PFO on c-TEE. Prescribed antithrombotic treatment was
acetylsalicylic acid 100 to 300mgo.d. (n = 23), clopidogrel
75mgo.d. (n = 18), and warfarin 5mgo.d. (n = 6).
Patients were started on warfarin if they had prothrombotic
conditions, history of deep venous thrombosis, coexisting
ASA, a lacunar infarct or infarct involving less than 1/3 on
the MCA territory, and if the risk of bleeding was deemed
acceptable based on age, cognitive status, comorbidities,
presence of a caregiver, and compliance to treatment. Nine
patients (15.7%) were referred to experienced interventional
cardiologists for catheter PFO closure: all were younger
than 55 years, had moderate to severe shunt on ultrasound
studies, and all preferred the percutaneous PFO closure
instead medical treatment. Treatment with acetylsalicylic acid
100mg o.d. was started after the procedure. The interventional
procedure was uneventful in all patients and no residual
shunt was observed in none of the treated patients.
There were no diﬀerences between patients with and
those without a PFO at two years in motor and functional
outcome measure (Table 2). The rates of recurrent stroke
and TIA did not signiﬁcantly diﬀer between patients with
and without a PFO: 0.0% versus 1.4% at 1 week, 1.7%
versus 2.7% at 1 month, and 3.5% versus 4.2% at 3 months,
respectively. The two-year rate of recurrent stroke or TIA
was 5/48 (10.4%) in medically treated PFO patients and
6/72 (8.3%) in PFO-negative patients (P = 0.65). In PFO-
positive patients the recurrent event occurred at 1, 4, 15
(n = 2), and 23 months after the index event; alternative
causes for recurrent stroke were detected in all patients: an
ulcerated aortic plaque was detected in 3 patients, while
atrial ﬁbrillation was diagnosed in 2 patients; of note, atrial4 ISRN Neurology
Table 2: Diﬀerences in clinical and radiological characteristics of
the index event and two-year outcome between patients with a
PFO conﬁrmed by combined ultrasound approach and those with
negative c-TCD study for RLS (i.e., PFO-negative patients).
PFO(+)
patients
n = 57
PFO(−)
patients
n = 72
P value
Index event: TIA/stroke, n (%) 10
(17.5%) 20 (27%) 0.1
Single/multiple/no acute lesion, n 37/10/10 35/17/20 0.1
Anterior circulation stroke (MCA),
n (%) 32 (56%) 40 (55%) 0.78
Symptoms on awakening, n (%) 10
(17.5%) 8 (11%) 0.09
Onset NIHSS score, mean (±SD) 5 (±4) 6 (±5) 0.3
24-hour NIHSS score, mean (±SD) 3 (±3) 5 (±4) 0.04
Discharge NIHSS score, mean
(±SD) 2( ±3) 3 (±3) 0.11
Days of in-hospital stay, mean
(±SD)
4.4
(±2.1)
4.5
(±2.7) 0.3
Three-month outcome
NIHSS score, mean (±SD) 2 (±2) 2 (±2) 0.28
mRS score, mean (±SD) 2 (±1) 1 (±2) 0.35
BI score, mean (±SD) 92 (±24) 97 (±25) 0.19
Two-year rate of stroke recurrence
or death
5/48
(10.4%)∗
6/72
(8.3%) 0.65
MCA indicates middle cerebral artery; NIHSS: National Institute of Health
Stroke Scale; mRS: modiﬁed Rankin Scale; BI: Barthel Index. ∗9/57 (15.8%)
patients underwent to percutaneous PFO closure and no recurrent events or
death were recorded in this group.
ﬁbrillation was an incidental ﬁnding during the follow-up
in 2 other patients. In PFO-negative patients the recurrent
e v e n to c c u r r e da t7d a y s ,a t3 ,9 ,1 8 ,a n d2 1m o n t h sa f t e r
the index event; 2 patients died at 1 and 7 months (one
massive intracranial bleeding while on warfarin, and one
fatal myocardial infarction). An intracardiac thrombus was
detected at the time of the recurrent stroke in one patient,
while a large aortic plaque was detected in another patient
who had recurrent stroke. All patients treated with percuta-
neous PFO closure (n = 9) were alive after two years, and
none of them had recurrent cerebrovascular events.
4. Discussion
We investigated the clinical beneﬁt of early screening for
PFO in patients with an acute ischemic stroke or TIA
of undetermined etiology. The rate of early and two-year
recurrent stroke or TIA in patients with a PFO under best
medical treatment was compared to those of patients with
no evidence of a PFO. The rates of recurrent stroke and
TIA in PFO and no-PFO patients in the short-term did not
signiﬁcantlydiﬀerbetweenthetwogroups:0.0%versus1.4%
at 1 week, 1.7% versus 2.7% at 1 month, and 3.5% versus
4.2% at 3 months, respectively. These rates are lower than
those previously observed in patients with undetermined
stroke etiology: the risk of recurrent cerebrovascular events
observed by Lovett et al. [14] was 2.3% at 7 days, 6.5%
at 1 month, and 9.3% at 3 months, which were similar to
those observed in cardioembolic strokes. However, in this
study, the analysis was not restricted to patients with PFO.
Ongoing randomized controlled studies should be able to
provide further information on early rate of adverse events
in PFO patients [7, 8]. In our study, the rate of recurrent
cerebrovascular events did not signiﬁcantly diﬀer between
PFO medically treated patients and no-PFO patients (10.4%
and 8.3%, resp.; P = 0.65), where a relative risk (RR) of 1.25
for the presence of a PFO wasobserved. In earlier studies, the
event rate (recurrent stroke or death) in patients with PFO
younger than 55 years was relatively low, being about 2.0%
(1.6–2.4%) per year, with a reported average recurrence rate
for stroke or TIA in medically treated patients of 4.0% for
the ﬁrst year and 8.6% within 2 years [2, 22, 23]. In a recent
meta-analysis of 15 studies [24] the pooled absolute rate of
recurrent ischemic stroke or TIA at one year in patients with
PFO treated medically was 4.0% (95% CI 3.0 to 5.1) while
the rate of recurrent ischemic stroke was 1.6% (95% CI 1.1
to 2.1). The pooled RR for recurrent ischemic stroke or TIA
in patients compared to those without a PFO was 1.1 (95%
conﬁdence interval (CI) 0.8 to 1.5). For ischemic stroke, the
pooled RR was 0.8 (95% CI 0.5 to 1.3). Al o wr e c u r r e n c er a t e
of stroke has been recently reported in 108 young patients (aged
18–45years)withcryptogenicischemicstrokewithandwithout
PFO [25]. In this long-term follow-up study (patients were
followed up to 66 months) the average annual rate of recurrent
cerebral ischemia was 1.1% and 1.6% for patients with and
without PFO, respectively. In this study the recurrence rate did
not increase with the presence of PFO, ASA, or other variables.
Taken together, these data indicate that the risk of
recurrent stroke after a cryptogenic stroke is not signiﬁcantly
increased in patients with PFO under medical treatment as
compared to patients without a PFO. As recently reported by
single centre [26, 27], as well as by a multicenter Italian study
[28], we also observed that percutaneous PFO closure may be
superior to medical treatment in preventing stroke recurrence.
However, there is evidence suggesting that this approach may
be less eﬀective in older patients [29].
Diﬀerences in the rates of recurrent cerebrovascular
events may be explained by great heterogeneity among
studies. First, we observed a signiﬁcant female prevalence
among patients with a PFO compared to PFO-negative
patients (48% versus 34%), which was similar to the
percentages reported by Lamy et al. (48% versus 38%;
P = 0.02) [30]. In a recent meta-analysis [24]a n dw i t h
the exception of one Italian study [22], a male prevalence
was reported either in studies with or in those without a
non-PFO comparison group. A diﬀerence in sex prevalence
might be related to undetermined factors predisposing
to paradoxical embolism, but this remains speculative.
Second, in our study stroke severity at onset did not diﬀer
between patients with and without a PFO, strokes were of
mild severity, and the 3-month outcome was good in both
groups. Stroke severity in PFO patients has been rarely
reported in published series: in the study of Bogousslavsky
et al. [23], a low rate of stroke recurrence was contrasted
with the severity of initial stroke, which was disabling inISRN Neurology 5
one-half the patients. Further, in their study there were fewer
TIAs (16% versus 23% in our study) and an alternative
cause of stroke was present in 16% of patients, usually
cardiac (atrial ﬁbrillation, severe mitral valve prolapse,
akinetic left ventricular segment); conversely, in the study
of Lamy et al. [30], more than half of patients with PFO
had mild strokes as measured by an mRS of 0-1, and the
outcome was favourable in more than 60% of cases in the
study of Arauz et al. [25]. Third, our patients were older
compared to previous reports (about 2/3 of patients were
older than 55 years). The slightly increased two-year rate of
recurrent cerebrovascular events observed in our study as
compared to previous analyses might be attributed to the
inclusion of patients with classic vascular risk factors for
stroke and older than 55 years, who are at higher risk of
developing factors associated with stroke recurrence in
cryptogenic stroke as aortic arch plaque [31], or atrial ﬁbril-
lation (which was diagnosed at stroke recurrence in two
PFO patients, and it was an incidental ﬁnding at follow-up
in two other PFO patients). Further, in our study, a PFO was
associated with ASA in 41% of patients, which is higher than
previously reported (17–24%) [20, 30, 32, 33]. However,
whether ASA alone or in association with a PFO confers
an increased risk of stroke recurrence in medically treated
patients is still debated [2, 3, 20, 34]. Finally, although not
signiﬁcant, we observed that patients with a PFO had more
frequently strokes-on-awakening. This has been previously
reported and associated with obstructive sleep apnoea caus-
ing right atrial pressure elevation during the night resulting
in RLS through a PFO [35]. We recently observed that the
administration of a single oral dose of sildenaﬁl (an inhibitor
of phosphodiesterase type 5) is able to aﬀect the interatrial
pressure gradient by acting on pulmonary resistances thus
reducing severity of RLS on c-TCD [36]. A change in RLS
volume on c-TCD ultrasound over time has been recently
observed in 1/3 of patients with cryptogenic stroke [37].
These data suggest that large multicentre observational stud-
ies are warranted in order to discriminate subgroups of
PFO patients at higher risk of stroke recurrence from those
with incidental PFO as well as to develop new therapeutic
approaches for secondary stroke prevention based on cardiac
and pulmonary hemodynamic parameters.
This study has some limitations. This was a single centre
observational study, with a relatively small sample size, and
our results cannot be generalized. Further, we did not sys-
tematically investigate those age-related factors thought to
increase the risk of paradoxical embolism (i.e., pulmonary
artery pressure, prothrombotic states, deep venous throm-
bosis) as well as their change over time. In addition, we did
not test patients for persisting RLS at follow-up examination
[37].
In conclusion, while pending evidence-based guidelines
for PFO management [7, 8], all available treatment options
and drawbacks keep to be explained and oﬀered to the
patient, and the patient’s preference and fear should be
taken into account [38]. In this setting, single-centre stud-
ies performed in highly selected stroke populations may
guide personalized prevention treatment and test adjuvant
treatment options based on the increasing insight into the
pathophysiology of stroke in patients with PFO.
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